title: Third-party reimbursement issues during a phase I trial of interleukin-2.
authors: N J
authors: NJ
authors: Vogelzang
authors: J M
authors: JM
authors: Richards
mesh_terms: D004341:Drug Evaluation / Q000191:economics*; D006801:Humans; D007349:Insurance, Health, Reimbursement; D007376:Interleukin-2 / Q000627:therapeutic use*; D014481:United States
chemical_list: D007376:Interleukin-2